How Does the FGFR3 Gene Cause Achondroplasia?

When a child has achondroplasia, their bones grow differently because of a change—often called a mutation or variant—in a specific gene known as FGFR3. To put it simply, the FGFR3 gene provides instructions for making a protein that acts like a “brake pedal” for bone growth ^[1][2]. In achondroplasia, this mutation causes the gene to be turned “on” all the time, much like a brake pedal that is pressing too hard or is partially stuck down ^[3][4][5]. This constant braking signal prevents the body from turning cartilage into bone as quickly as it normally would, leading to the shorter bones characteristic of the condition ^[1][5].

The Role of the FGFR3 “Brake Pedal”

In every person, the FGFR3 gene plays a vital role in managing how bones lengthen and grow. Most of the bones in our arms, legs, and spine begin as a softer tissue called cartilage, which gradually hardens into solid bone through a process called endochondral ossification ^[1][2].

For this process to happen correctly, the body needs a balance of signals telling the bones to grow (the “gas pedal”) and signals telling them to slow down (the “brake pedal”). The FGFR3 protein is a natural brake ^[1]. When working typically, it ensures that bones do not grow too quickly and that they form the right shape.

What Happens in Achondroplasia?

In achondroplasia, a small spelling change in the DNA of the FGFR3 gene creates what doctors call a gain-of-function mutation ^[3][4]. While “gain of function” might sound like the gene is working better, it actually means the gene is overactive ^[4][5][6].

Because the FGFR3 gene is overactive:

• The Brake Stays On: The receptor constantly sends a “stop” signal to the growth plates at the ends of the bones, even when it shouldn’t ^[3][1].
• Cartilage Cells Slow Down: The cells in the cartilage (called chondrocytes) do not multiply or mature as quickly as they normally would ^[1][5].
• Bone Conversion is Delayed: Because the cartilage cells are slowed down, the process of turning that cartilage into hard bone is interrupted ^[1][2].

This biological traffic jam primarily restricts the long bones of the arms and legs, which rely heavily on this cartilage-to-bone process to grow longer ^[4][1]. However, it also affects the development of the spine and the base of the skull, which is why people with achondroplasia may experience related complications like spinal stenosis or sleep apnea over time ^[4][2].

Why This Biology Matters for Treatment

Understanding how the FGFR3 brake pedal works isn’t just about knowing why bones grow differently in achondroplasia—it is also the key to how modern treatments work.

Because researchers know that achondroplasia is caused by this overactive signaling, they have developed medicines that aim to bypass or lift the stuck brake ^[7][8]. For example, modern treatments, such as targeted medications (like vosoritide), are designed to counteract these overly strong “stop” signals and help the cartilage resume its normal process of turning into bone ^[9][10].

It is important to note, however, that these targeted treatments must be administered during childhood while the growth plates are still “open” and actively forming bone ^[11]. Once the growth plates fuse—typically in late adolescence—the bones can no longer lengthen, and these medications will no longer impact bone growth ^[11].